Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D Supplementation in Parkinson's Disease
NCT06539260Phase 1Completed
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vitamin d in Parkinson's disease (PD) and Vitamin D deficiency (VDD), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: Th17 expression level at 3 months, Treg expression level at 3 months and 1 more. Started Jan 2023; status: completed.
02
Drugs
vitamin d
03
Conditions
Parkinson's disease (PD)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on NCT06539260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539260.